Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (8): 718-723.doi: 10.35541/cjd.20230054

• Expert Commentary • Previous Articles     Next Articles

Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis

Song Zhiqiang, Chen Qiquan, Ge Lan   

  1. Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing 400038, China
  • Received:2023-02-06 Revised:2023-05-21 Online:2023-08-15 Published:2023-08-07
  • Contact: Song Zhiqiang
  • Supported by:
    National Natural Science Foundation of China(82273529)

Abstract: 【Abstract】 The pathogenesis of atopic dermatitis is complex, and mainly related to genetic background, environmental stimuli, epidermal barrier defects, immune disorders, and other factors. Using Th2-type inflammatory cytokines and the JAK-STAT pathway as therapeutic targets has become a hotspot in drug development for atopic dermatitis. By now, multiple monoclonal antibodies and small-molecule drugs have been successfully used in the treatment of atopic dermatitis, marking that the treatment of atopic dermatitis has entered the era of precision therapy and targeted therapy.

Key words: Dermatitis, atopic, Molecular targeted therapy, Biological agents, Janus kinases, Pathogenesis, Precision therapy